CDK4 and prostate carcinoma: This truncated fumaramide handle maintainedrobust degradation of BRD4 and expanded the scope of neo-substratetargets, including CDK4/6, SMARCA2/4, and notably, the androgen receptor(AR) and its therapeutically challenging truncation variant AR-V7in androgen-independent prostate cancer cells.